Navigation Links
Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma today announced, that the abstract entitled “Preliminary Results of a Phase I/II-Study in Pancreatic Carcinoma, Malignant Melanoma, and Colorectal Carcinoma with the TGF-beta2 Inhibitor AP 12009” has been selected for poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) as a 7-day continuous infusion every other week. “The first milestone of the study has been achieved, as the maximum tolerated dose was determined with this treatment schedule”, explains Hubert Heinrichs, M.D., Ph.D., Chief Medical Officer at Antisense Pharma. Patient recruitment is still ongoing in study sites in Germany as further dose escalations with a modified dosing schedule are now performed. The design of the study, first efficacy and safety data will be presented at the poster presentation (Poster Board No. AA5, Abstract ID 4607) on June 4th 2007 from 8:00 a.m. to 12:00 p.m. in the session “Gastrointestinal (Noncolorectal) Cancer”. Prof. Thomas Seufferlein, Vice Head of the Department of Internal Medicine at the University of Ulm and Principal Investigator of the Phase I/II-Study will be available for questions from 11:00 a.m. to 12:00 p.m. at the poster in Hall A2 on Level 3 of McCormick Place South Building.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization.


'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase data Systemic Application the TGF beta2 inhibitor Presented
(Date:9/23/2014)... , Sept. 23, 2014 Nuclear medicine ... 2015. Radiopharmaceuticals/ Nuclear are drugs that ... imaging field to diagnose and treat diseases. ... Increasing awareness for radiopharmaceuticals, and ready availability of ... market. Furthermore, increased public awareness and use of ...
(Date:9/23/2014)... 23, 2014 FDNA ... d,une série de démonstrations personnelles   ... domaine de l,analyse de la dysmorphologie assistée ... n° 1035 lors de la réunion ASHG 2014, qui ... , en Californie. FDNA présentera la ...
(Date:9/23/2014)... Dans les secteurs ... ferroviaire ou encore l,énergie, les machines, de ... à leurs données. Ces données de masse ... cœur des voitures, trains, avions, appareils médicaux… ... le nombre de machines connectées d,ici 2020. ...
Breaking Medicine Technology:Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019) 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Altran transforme le big data du monde industriel en nouveau business 2
... ThermalTherapeutic Systems, Inc. (TTS), maker of portable ... F.H. Smith as President and Chief Executive Officer. Mr. ... operational executive in the high-tech sector, focused on biotech, ... F. Vennare will transition to the role of Executive ...
... 2011 Bay Sleep, the West Coast,s largest and ... its newest, state-of-the-art sleep clinic in Oakland, California.  Located ... Sleep,s 16th clinic open for business. Services include sleep ... dispensing CPAP and other therapies for patients diagnosed with ...
Cached Medicine Technology:ThermalTherapeutic Systems, Inc. Names Gardiner F. H. Smith, President and Chief Executive Officer 2Bay Sleep Clinic Continues Growth in California and Beyond 2
(Date:9/23/2014)... the first year follow a set of predictable ... and first words. However, previous research had not ... between hearing and deaf infants. Now, University of ... motivated by infants, ability to hear their own ... received cochlear implants to help correct their hearing ...
(Date:9/23/2014)... found that FDG-PET technology is less accurate in ... where infections like histoplasmosis or tuberculosis are common. ... could lead to unnecessary tests and surgeries for ... , Histoplasmosis and other fungal diseases are linked ... droppings and are found in soils. , The ...
(Date:9/23/2014)... September 23, 2014 World of Home ... philanthropic support. Most recently, the gym has been raising ... Fitness program. Throughout the year, World of Home Fitness ... charitable causes. , Over the summer, World of Home ... Through their Ageless Fitness program, participants helped feed seniors ...
(Date:9/23/2014)... 23, 2014 As a consumer in ... a purchase. It’s difficult to trust testimonials that are ... them to manipulate their customers into saying anything. , ... they tend to lack in depth coverage on a ... was founded to fix this issue and focus on ...
(Date:9/23/2014)... Karen Pallarito HealthDay Reporter ... if doctors and hospitals got paid for providing better ... better data for making informed health choices. A ... is headed. The report, from the IMS Institute for ... -- recent events expected to alter the delivery of health ...
Breaking Medicine News(10 mins):Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3
... CHICAGO For years, it was believed that obese women ... body fat actually protected against bone loss. However, a study ... of North America (RSNA) found that having too much internal ... bone health. "We know that obesity is a major ...
... , CAMBRIDGE, Mass. (November 29, 2010) Whitehead Institute ... the microRNA 125b (miR-125b) can independently cause leukemia and ... this week,s online edition of the Proceedings of the ... in many cancers, but in humans and mice, can ...
... With the emergence of an epidemic of obesity and type ... habits that may affect the risk of metabolic diseases is ... drinkers tend to have about 30% lower risk of developing ... tend to be at lower risk of developing metabolic ...
... Goodwin HealthDay Reporter , MONDAY, Nov. 29 (HealthDay ... teens over the last few decades, with some of the ... a new report. In one startling statistic cited in ... and Quality found that hospitalizations for eating disorders jumped by ...
... iridescence of a butterfly,s wing, investigators at the University ... and Applied Sciences have developed a color-changing patch that ... indicate the strength of exposure to blasts from explosives ... color change to the intensity of exposure to provide ...
... , MONDAY, Nov. 29 (HealthDay News) -- Children and teens ... triclosan may be at increased risk for hay fever and ... can actually make people sick, researchers say. The study ... bisphenol A (BPA) may weaken an adult,s immune system. ...
Cached Medicine News:Health News:Belly fat puts women at risk for osteoporosis 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:Moderate alcohol consumption lowers the risk of metabolic diseases 2Health News:Rate of Eating Disorders in Kids Keeps Rising 2Health News:Rate of Eating Disorders in Kids Keeps Rising 3Health News:Color-changing 'blast badge' detects exposure to explosive shock waves 2Health News:Too Much Hygiene May Affect Immune System, Study Suggests 2
The Bledsoe Flatform Boot is designed with a flat innersole for procedures where toe dorsiflexion is not permissible....
The Bledsoe Achilles Boot saves time by eliminating casting series required to stretch the achilles tendon during rehab....
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Bauerfeind™ AchilloTrain® The viscoelastic insert runs ... application of pressure and targeted intermittent ... reduction of painful irritation of the ... integrated viscoelastic heel wedge (raises heel ...
Medicine Products: